Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Limited
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A multi-centre, double blind, double-dummy, placebo-controlled, randomised, adaptive, dose-range study to evaluate the dafety and efficacy of SB-773812 administered once daily for 12 weeks in adults with schizophrenia
The primary objective is to compare the efficacy of SB-773812 to placebo in the treatment of patients diagnosed with schizophrenia.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study
To describe the long-term safety and tolerability of oral eltrombopag treatment of subjects with ITP with or without concomitant ITP medication.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of either 20mg or 200mg GW876008, a CRF1 antagonist, to adult patients with irritable bowel syndrome
To test the hypothesis that acute therapeutic effects of GW876008 in IBS patients will reverse stress-induced visceral hypersensitivity as evidenced by changes in RMBF and/or thresholds for perception...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400mcg administered once-daily in the morning via DISKUS™ dry-powder inhaler) compared with salmeterol (50mcg administered twice-daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD
The primary objective is to evaluate the safety and tolerability of 2 dosages of GW642444H (100 and 400mcg administered once-daily for 2 weeks) versus salmeterol and placebo in subjects with moderate ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A study to assess the efficacy and safety of Sirukumab in the treatment of patients with Giant Cell Arteritis, using multiple sites, and an untreated patient group Estudio para evaluar la eficacia y seguridad de sirukumab en el tratamiento de pacientes con arteritis de células gigantes, en multiples centros y con un grupo de pacientes sin tratar
To investigate the efficacy of sirukumab (100 mg q2w for 12 months) as compared to placebo, each administered in addition to a 6-month prednisone treatment regimen Investigar la eficacia de siru...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Gonorrhea in Adults
To demonstrate the effectiveness of single oral doses of GSK2140944 to treat adult subjects with uncomplicated urogenital gonorrhea caused by N. gonorrhoeae
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV
- Whether a single oral dose of GW597599, when administered in combination with IV ondansetron hydrochloride, improves the prophylaxis against emesis (defined as vomiting or retching) during the first...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptying
To measure the effect of co-administration of GSK962040 on levodopa pharmacokinetic exposure in subjects with Parkinson’s disease with delayed gastric emptying
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
Clinical study using the drug GSK525762 in subjects with hematologic malignancies
PART 1 To determine the safety, tolerability and maximum tolerated dose (MTD), following once daily (QD) and/or twice daily (BID) dosing schedules, establishing the recommended Phase 2 dose (RP2D) o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
To determine whether there is a difference in colonic mucosal blood flow determined by Laser Doppler Flowmetry (LDF) in subjects who have taken 6 days BID dosing of 1mg alosetron vs. placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
Suivant